Belmont Global Advisors’s Fate Therapeutics FATE Stock Holding History

Belmont Global Advisors’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	$468K	Sell	150,000 -250,000	-63%	-$607K	0.44%	45
2016 Q2	$680K	Sell	400,000 -82,000	-17%	-$149K	0.65%	30
2016 Q1	$868K	Buy	482,000 +317,000	+192%	+$653K	0.88%	26
2015 Q4	$556K	Buy	+165,000	New	+$694K	0.72%	43

Other funds holding FATE

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

PVMCV

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BOTOTLSJU

Board of Trustees of The Leland Stanford Junior University Redwood City, California $533M AUM 65.58% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

LOAMU

Lombard Odier Asset Management (USA) New York $727M AUM 41.88% 1-Year Est. Return

Belmont Global Advisors's FATE Position: Q3 2016 in Review

Belmont Global Advisors reduced its Fate Therapeutics (FATE) stake by 63% in Q3 2016, selling an estimated $607K and leaving 150,000 shares worth $468K. The position accounts for 0.44% of the portfolio, ranked #45.

Belmont Global Advisors first reported a position in FATE in Q4 2015 and has held it in 4 quarters since. The position peaked at $868K in Q1 2016. 40 funds tracked by Wall St. Rank hold FATE as of Q3 2016.

Belmont Global Advisors held 150,000 shares of Fate Therapeutics worth $468K as of Q3 2016.
Belmont Global Advisors sold 250,000 Fate Therapeutics shares in Q3 2016, an estimated $607K.
Fate Therapeutics made up 0.44% of Belmont Global Advisors's portfolio in Q3 2016, its #45 holding.
Belmont Global Advisors first reported a position in Fate Therapeutics in Q4 2015 and has held it in 4 quarters since.
Belmont Global Advisors's Fate Therapeutics position peaked at $868K in Q1 2016.
40 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2016.

Based on Belmont Global Advisors's 13F filing for Q3 2016, filed 14 Nov 2016.